Glioblastoma tumorspheres treated with perphenazine (PER) and temozolomide (TMZ)

Glioblastoma (GBM), a primary malignant brain tumor, has a poor prognosis, even with standard treatments such as radiotherapy and chemotherapy. In this study, we explored the anticancer effects of the synergistic combination of perphenazine (PER), a dopamine receptor D2/3 (DRD2/3) antagonist, and temozolomide (TMZ), a standard treatment for GBM, in patient-derived human GBM tumorspheres (TSs). GBM TSs were treated with PER, TMZ, and combined of both, then their respective gene expression was measured by RNA sequencing.

胶质母细胞瘤（Glioblastoma, GBM）是一种原发性恶性脑肿瘤，即便采用放疗、化疗等标准治疗手段，其预后仍较差。本研究针对多巴胺受体D2/3（DRD2/3）拮抗剂奋乃静（perphenazine, PER）与胶质母细胞瘤标准治疗药物替莫唑胺（temozolomide, TMZ）协同联合的抗癌效果展开探究，实验模型采用患者来源的人胶质母细胞瘤肿瘤球（TSs）。实验中，我们将GBM肿瘤球分别用PER、TMZ以及二者联合处理，随后通过RNA测序（RNA sequencing）检测各组的基因表达水平。